Hydromorphone intrathecal - CNS Therapeutics

Drug Profile

Hydromorphone intrathecal - CNS Therapeutics

Latest Information Update: 17 Feb 2016

Price : $50

At a glance

  • Originator CNS Therapeutics
  • Developer CNS Therapeutics; Mallinckrodt LLC
  • Class Morphine derivatives; Opioid analgesics; Small molecules
  • Mechanism of Action Opioid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Pain

Most Recent Events

  • 17 Feb 2016 Hydromorphone is still in phase III clinical trials for Pain in USA (Intrathecal)
  • 01 Jun 2013 CNS Therapeutics initiates enrolment in a phase III trial for Pain in USA (NCT01709747)
  • 16 Feb 2013 Phase-III clinical trials in Pain in USA (Intrathecal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top